{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-069258","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2025-07-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.366144+00:00","generated_at":"2026-05-18T05:26:21.066965+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Acura receives two $100K loans from AD Pharma; warns of possible operations halt if no further financing by Aug 2025","bullets":["Principal on secured note rises to $8,394,279 with ~$740K accrued interest; interest rate 5.25%.","Loans of $100K each on July 3 and July 18, 2025 from Abuse Deterrent Pharma, LLC (AD Pharma).","Without additional financing by early August 2025, company may furlough employees or seek bankruptcy protection.","AD Pharma owns ~65% of outstanding common stock (excludes warrant for 10M shares).","Funds used for day-to-day operations; no assurance of further financing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-069258","json":"https://secwatch.observer/filing/0001104659-25-069258.json","markdown":"https://secwatch.observer/filing/0001104659-25-069258.md","text":"https://secwatch.observer/filing/0001104659-25-069258.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465925069258/0001104659-25-069258-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465925069258/tm2521314d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:26:21.066965+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5252e95b48cd2a94d93b5b53ddfb806091fed9ae","claim":"ACURA PHARMACEUTICALS, INC incurred loan of $8,394,279 with Abuse Deterrent Pharma, LLC at 5.25%.","evidence_excerpt":"On each of July 3, 2025 and July 18, 2025, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (\"AD Pharma\"). These loans combined with previous loans made to the Company and combined with the $2,319,279 under the November 10, 2022 Amended Consolidated and Restated Secured Promissory Note, now has a principal balance of $8,394,279 with accrued interest of approximately $740,000 as of July 21 2025, and bears interest at 5.25% (\"Note\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465925069258/0001104659-25-069258-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$8,394,279"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"6443119b9a543ba49760b71c460e248196d4efa3","claim":"ACURA PHARMACEUTICALS, INC completed an acquisition involving Abuse Deterrent Pharma, LLC.","evidence_excerpt":"Item 2.01 – Completion of Acquisition or Disposition of Assets The contents of all Items 1.01 are incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465925069258/0001104659-25-069258-index.htm","confidence":0.1,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}